End stage liver disease results in a complex and variably severe failure of hemostasis that predisposes to abnormal bleeding. The diverse spectrum of hemostatic defects includes impaired synthesis of clotting factors, excessive fibrinolysis, disseminated intravascular coagulation, thrombocytopenia, and platelet dysfunction. Hemostasis screening tests are used to assess disease severity and moni...

Case description Mrs Z. was a 63-year-old woman with chronic hepatitis C infection and end-stage liver disease (ESLD). She had had 2 hospital admissions in the past 6 months for complications related to her ESLD, most recently for spontaneous bacterial peritonitis (SBP). Mrs Z. also had a history of refractory ascites requiring paracentesis every 2 weeks and large esophageal varices that had no...

BACKGROUND Chronic liver disease is characterized by inflammation and fibrosis. As a consequence angiogenesis leading to new vasculature may have prognostic value in disease progression. Interfering with angiogenesis may be a potential target to avoid progression of liver disease. Hence we planned to evaluate the CD34 and vascular endothelial growth factor (VEGF), the markers for angiogenesis i...

This chapter will focus on studies within the last 5 years of nutrition in end stage liver disease, but earlier studies illustrating the present state of affairs will also be mentioned. The first part will focus on descriptive epidemiological studies that help to set the scene for the intervention studies, which will be described in the second part. Each part will discuss liver cirrhosis, acute...

Among various complications of end-stage liver disease, hepatorenal syndrome has the highest mortality. Patients with both end-stage liver disease and end-stage renal disease are candidates for combined liver-kidney transplantation. However, patients with cirrhosis with decompensation presenting in the form of hepatorenal syndrome, are also likely candidates for the procedure. Herein, we presen...

Background: HCV chronic infection is a leading cause of end-stage liver disease and transplantation. The aim our study was to assess the benefits novel anti-HCV therapeutic approaches in obtaining viral clearance, reducing inflammation, regression fibrosis, improvement liver-related morbidity mortality.

conclusions nx-dcp correlated positively with fibrosis stage and could discriminate well between hcv-related patients with or without significant fibrosis. moreover, nx-dcp had a similar predictive ability to the abovementioned models, and thereby could be a new noninvasive prediction tool for fibrosis. results increase in serum nx-dcp was significantly related to increase in fibrosis stage (p ...